Search
forLearn
5 / 801 resultslearn glutamic acid
learn capilia longa
learn Lipodermal base
learn Aminobutyric Acid
Research
5 / 134 results
research The triple rotation scalp flap revisited: a case of reconstruction of cicatricial pressure alopecia
The triple rotation scalp flap technique successfully reconstructed a man's scalp with natural-looking hair growth and minimal scarring.
research Surgical Anatomy of the Scalp
Understanding scalp anatomy is crucial for successful and safe scalp surgery.
research Deep Plane Fixation in Integumental Surgery
Deep Plane Fixation in scalp surgeries allows for more tissue removal with less tension, leading to better healing and less scarring.
research Deep Plane Fixation in Integumental Surgery
Deep Plane Fixation in scalp surgeries allows for more tissue removal with less tension and minimal scarring.
research Tissue Expanders in Post-Burn Alopecia: With or Without Galeotomies
Using tissue expanders with galeotomies for post-burn alopecia is faster and has fewer complications.
Community Join
5 / 1000+ resultscommunity Scalp tension and thickness of the galea aponeurotica, inflammation and potential treatment pathways
Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.
community Setipiprant/PGE2 feedbacks?
community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community So, what's the consensus on bimatoprost, lanatoprost or travoprost for AGA/MPB?
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.